Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis

D Ilic, M Djulbegovic, JH Jung, EC Hwang, Q Zhou… - bmj, 2018 - bmj.com
Objective To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to
screen for prostate cancer. Design Systematic review and meta-analysis. Data sources …

Prostate cancer mortality in the Finnish randomized screening trial

TP Kilpeläinen, TL Tammela, N Malila… - Journal of the …, 2013 - academic.oup.com
Background Prostate cancer (PC) screening with prostate-specific antigen (PSA) has been
shown to decrease PC mortality by the European Randomized Study of Screening for …

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer

MJ Roobol, R Kranse, CH Bangma, AG van Leenders… - European urology, 2013 - Elsevier
Background Evidence from randomized trials on the effects of screening for prostate cancer
(PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective …

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

J Hugosson, MJ Roobol, M Månsson, TLJ Tammela… - European urology, 2019 - Elsevier
Abstract Background The European Randomized study of Screening for Prostate Cancer
(ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening …

Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence

JH Hayes, MJ Barry - Jama, 2014 - jamanetwork.com
Importance Prostate cancer screening with the prostate-specific antigen (PSA) test remains
controversial. Objective To review evidence from randomized trials and related modeling …

Prostate-specific antigen-based screening: controversy and guidelines

EH Kim, GL Andriole - BMC medicine, 2015 - Springer
Although prostate-specific antigen (PSA) screening has improved the detection of prostate
cancer, allowing for stage migration to less advanced disease, the precise mortality benefit …

Screening and prostate-cancer mortality in a randomized European study

FH Schröder, J Hugosson, MJ Roobol… - New England journal …, 2009 - Mass Medical Soc
Background The European Randomized Study of Screening for Prostate Cancer was
initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen …

Prostate-specific antigen–based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force

JJ Fenton, MS Weyrich, S Durbin, Y Liu, H Bang… - Jama, 2018 - jamanetwork.com
Importance Prostate cancer is the second leading cause of cancer death among US men.
Objective To systematically review evidence on prostate-specific antigen (PSA)–based …

[HTML][HTML] Prostate cancer screening with prostate-specific antigen: A guide to the guidelines

S Cabarkapa, M Perera, S McGrath… - Prostate …, 2016 - Elsevier
Background Prostate cancer remains the most common non-skin cancer malignancy in men.
Prostate-specific antigen (PSA) is recognized as a biomarker for the diagnosis, monitoring …

Prostate cancer mortality reduction by prostate-specific antigen–based screening adjusted for nonattendance and contamination in the European Randomised Study …

MJ Roobol, M Kerkhof, FH Schröder, J Cuzick… - European urology, 2009 - Elsevier
BACKGROUND: Prostate-specific antigen (PSA) based screening for prostate cancer (PCa)
has been shown to reduce prostate specific mortality by 20% in an intention to screen (ITS) …